Literature Collection

7361

Perspectives on medication treatment for opioid use disorder in adolescents: Results from a provider learning series

Type: Journal Article

Authors: Michelle Peavy, Addy Adwell, Mandy D. Owens, Caleb J. Banta-Green

Year: 2023

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7362

Perspectives on Monitoring Youth with Ongoing Mental Health Problems in Primary Health Care: Family Physicians Are “Out of the Loop”

Type: Journal Article

Authors: Kyleigh E. Schraeder, Judith Belle Brown, Graham J. Reid

Year: 2018

Publication Place: New York

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7363

Perspectives on the opioid crisis from pain medicine clinicians

Type: Journal Article

Authors: G. W. Jay, R. L. Barkin

Year: 2018

Publication Place: United States

Topic(s):

Reference Links:

Export Citation: RIS

View details

7364

Perspectives on the opioid crisis from pain medicine clinicians

Type: Journal Article

Authors: G. W. Jay, R. L. Barkin

Year: 2018

Publication Place: United States

Topic(s):

Reference Links:

Export Citation: RIS

View details

7365

Perspectives on the roles and value of social work practice in neighborhood health centers and implications for the reimbursement of services

Type: Journal Article

Authors: Terry Mizrahi, Victoria M. Rizzo

Year: 2008

Publication Place: United States

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7366

Perspectives on trauma and the design of a technology-based trauma-informed intervention for women receiving medications for addiction treatment in community-based settings

Type: Journal Article

Authors: T. C. Saraiya, M. Swarbrick, L. Franklin, S. Kass, A. N. C. Campbell, D. A. Hien

Year: 2020

Publication Place: United States

Topic(s):

, ,

Reference Links:

Export Citation: RIS

View details

7367

Pharmacist integration into the medical home: Qualitative analysis

Type: Journal Article

Authors: M. Kozminski, R. Busby, M. S. McGivney, P. M. Klatt, S. R. Hackett, J. H. Merenstein

Year: 2011

Publication Place: United States

Abstract: OBJECTIVE: To determine the acceptance and attitudes of family medicine physicians, clinical and nonclinical office staff, pharmacists, and patients during pharmacist integration into a medical home. DESIGN: Qualitative study.Setting: Pittsburgh, PA, area from August 2009 to June 2010. PARTICIPANTS: Physicians, staff, pharmacists, and patients at four single-specialty family medicine office practices functioning as medical homes. MAIN OUTCOME MEASURES: Attitudes, acceptance, barriers, and problems identified by participants. RESULTS: A total of 84 interviews were conducted: 21 interviews with family medicine physicians, 26 with patient care staff, 9 with nonclinical staff, 13 with patients, 6 with pharmacists, and 8 with office managers. Five main themes emerged from each group regarding the integration of a pharmacist, including positive overall feeling; clinical, educational, and time-saving benefits to the various groups; challenges understanding the role of the pharmacist; improved workflow and integration resulting from pharmacist flexibility and motivation; and suggestions to increase the pharmacists' time in each office. Pharmacists felt that they were accepted within 6 months of the integration process and that time management was a challenge. CONCLUSION: Participants felt that inclusion of a pharmacist into their practice improves the quality of patient care, provides a valuable resource for all providers and staff, and empowers patients. The initial concerns of the clinical and nonclinical staff disappeared within the first months of pharmacist integration. These results provide guidance to clinicians and insight into strategies for building a pharmacist-integrated medical home team.

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7368

Pharmacist utilization of opioid misuse and abuse interventions: Acceptability among pharmacists and patients in Detox

Type: Web Resource

Authors: Tegan Beechey Riley

Year: 2018

Topic(s):

, ,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

Export Citation: RIS

View details

7369

Pharmacist-provided services and community pharmacist integration into a patient-centered medical home: A qualitative study of primary care clinic staff perceptions

Type: Journal Article

Authors: K. A. Bates, R. A. Stafford, B. S. Teeter, T. Diemer, J. L. Thomas, G. M. Curran

Year: 2019

Publication Place: United States

Topic(s):

Reference Links:

Export Citation: RIS

View details

7370

Pharmacist-social worker interprofessional relations and education in mental health: a scoping review

Type: Journal Article

Authors: P. Boylan, J. Knisley, B. Wiskur, J. Nguyen, K. Lam, J. Hong, J. Caballero

Year: 2024

Topic(s):

Reference Links:

Export Citation: RIS

View details

7371

Pharmacist, prescriber, and drug policy expert opinions on gabapentinoid misuse

Type: Journal Article

Authors: J. R. Covvey, M. L. Blakely, R. Singh, A. M. Peckham, K. E. Evoy

Year: 2023

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7372

Pharmacists and opioid use disorder care during COVID-19: Call for action

Type: Journal Article

Authors: I. Mohammad, D. Berri, Tutag Lehr

Year: 2021

Topic(s):

, ,

Reference Links:

Export Citation: RIS

View details

7373

Pharmacists who screen and discuss opioid misuse with patients: Future directions for research and practice

Type: Journal Article

Authors: Gerald Cochran, Craig Field, Kenneth Lawson

Year: 2015

Topic(s):

,

Export Citation: RIS

View details

7374

Pharmacists: On the Front Lines

Type: Government Report

Authors: Centers for Disease Control and Prevention

Year: 2015

Publication Place: Atlanta, GA

Topic(s):

,

Disclaimer:

This grey literature reference is included in the Academy's Literature Collection in keeping with our mission to gather all sources of information on integration. Grey literature is comprised of materials that are not made available through traditional publishing avenues. Often, the information from unpublished resources can be limited and the risk of bias cannot be determined.

PDF (1160 KB)

Reference Links: PDF (1160 KB)

Export Citation: RIS

View details

7375

Pharmacists' different profiles characterization about opioid substitution treatments

Type: Journal Article

Authors: F. Etcheverrigaray, C. Betaud, F. Feuillet, M. Grall-Bronnec, P. Jolliet, C. Victorri-Vigneau

Year: 2016

Publication Place: France

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7376

Pharmacists' role and experiences with delivering mental health care within team-based primary care settings during the COVID-19 pandemic

Type: Journal Article

Authors: R. Ashcroft, A. Mathers, A. Gin, S. Lam, C. Donnelly, J. B. Brown, T. Kourgiantakis, K. Mehta, J. Rayner, D. Sur, K. Adamson, A. Kirvan, L. Dolovich

Year: 2024

Topic(s):

Reference Links:

Export Citation: RIS

View details

7377

Pharmacists’ nonprescription syringe dispensing perceptions and behaviors: A three-state descriptive analysis

Type: Journal Article

Authors: Nicholas E. Hagemeier, KariLynn Dowling-McClay, Mahnaz Baladezaei, Sabrina J. Curtis, Matthew Spence

Year: 2021

Topic(s):

,

Reference Links:

Export Citation: RIS

View details

7378

Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence

Type: Journal Article

Authors: A. S. Saber-Tehrani, R. D. Bruce, F. L. Altice

Year: 2011

Publication Place: England

Abstract: BACKGROUND: Psychiatric comorbidities among opioid-dependent patients are common. Many medications used to treat both conditions are metabolized through complimentary cytochrome P450 isoenzymes. When medication-assisted treatment for opioid dependence is concurrently used with psychotropic medications, problematic pharmacokinetic drug interactions may occur. METHODS: We reviewed relevant English language articles identified through the MedLine, Scopus, and Embase databases from 1950 to December 2009 using the specific generic names of medications and keywords such as pharmacokinetics and drug interactions with buprenorphine, methadone, and naltrexone. Selected references from these articles were reviewed. Additionally, a review was conducted of abstracts and conference proceedings from national and international meetings from 1990 to 2009. A total of 60 studies were identified and reviewed. RESULTS: Clinical case series and carefully controlled pharmacokinetic interaction studies have been conducted between methadone, buprenorphine, or naltrexone and some psychoactive medications. Important pharmacokinetic drug interactions have been demonstrated within each class of medications affecting either methadone and buprenorphine or psychoactive drugs. Few studies, however, have been conducted with naltrexone. CONCLUSIONS: Several interactions between methadone, buprenorphine, or naltrexone and psychoactive medications are described and may have important clinical consequences. To optimize care, clinicians must be alerted to these interactions.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7379

Pharmacokinetic Evaluation of Once-Weekly and Once-Monthly Buprenorphine Subcutaneous Injection Depots (CAM2038) Versus Intravenous and Sublingual Buprenorphine in Healthy Volunteers Under Naltrexone Blockade: An Open-Label Phase 1 Study

Type: Journal Article

Authors: M. Albayaty, M. Linden, H. Olsson, M. Johnsson, K. Strandgarden, F. Tiberg

Year: 2017

Publication Place: United States

Abstract: INTRODUCTION: CAM2038 q1w (once weekly) and q4w (once monthly) are investigational buprenorphine subcutaneous (SC) formulations based on FluidCrystal((R)) injection depot technology. These two drug products are being developed for opioid dependence treatment, with a target for once-weekly and once-monthly SC dosing. The rationale for developing two products with different dosing frequencies is that treatment strategies/routines, and hence different treatment preferences, can vary between patients, different stages of opioid maintenance treatment, and countries. This study evaluated the pharmacokinetics and safety of buprenorphine and norbuprenorphine following administration of CAM2038 q1w or q4w versus active controls. METHODS: Healthy volunteers were randomized to five treatment groups. All received a single intravenous dose of buprenorphine 600 microg, followed post-washout by a single dose of CAM2038 q4w 96 mg, a single dose of CAM2038 q4w 192 mg, or sublingual buprenorphine 8, 16, or 24 mg daily for 7 days, followed post-washout by a single dose of CAM2038 q4w 64 or 128 mg or four repeated weekly doses of CAM2038 q1w 16 mg. All subjects received daily naltrexone. RESULTS: Eighty-seven subjects were randomized. Median buprenorphine t max after CAM2038 q4w was 4-10 h (24 h for CAM2038 q1w); mean terminal half-life was 19-25 days (5 days for CAM2038 q1w). CAM2038 q4w showed dose-proportional buprenorphine release, with similar exposure to repeat-dose CAM2038 q1w at comparable monthly dose level. Both CAM2038 formulations showed complete absolute bioavailability of buprenorphine and 5.7- to 7.7-fold greater buprenorphine bioavailability versus sublingual buprenorphine. CAM2038 q1w and q4w were well tolerated; subjects' acceptance was higher for CAM2038 than for sublingual buprenorphine 1 h post-dose. CONCLUSIONS: The pharmacokinetic profiles of CAM2038 q1w and q4w versus sublingual buprenorphine support expected treatment efficacy with once-weekly and once-monthly dosing, respectively. CAM2038 formulations were safe and showed good local tolerability. TRIAL REGISTRATION: ISRCTN24987553. FUNDING: Camurus AB.

Topic(s):

Reference Links:

Export Citation: RIS

View details

7380

Pharmacokinetic Interactions between Buprenorphine/Naloxone and Raltegravir in Subjects Receiving Chronic Buprenorphine/Naloxone Treatment

Type: Journal Article

Authors: Douglas Bruce, David E. Moody, Diane Chodkowski, Laurie Andrews, Wenfang B. Fang, Jerdravee Morrison, Theresa L. Parsons, Gerald H. Friedland

Year: 2013

Topic(s):

Export Citation: RIS

View details